EndocrinologyBeginner

HOMA-B

Estimates pancreatic beta-cell function from fasting glucose and insulin.

Clinical Parameters

2 Variables
mg/dL
µU/mL (or mIU/L)

Awaiting Clinical Parameters

Configure the patient variables on the left and select Calculate Result to generate the clinical score and stratification.

Verified 2026 GuidelinesInstant Calculation
Jump to Formula & Clinical Protocol ↓
High Yield Prometric TopicEndocrinology & Metabolism

Tested on Gulf Medical Boards (DHA, SMLE, MOH & HAAD)

Clinical calculations and diagnostic scoring systems like HOMA-B frequently appear on Prometric exams. Master high-yield clinical vignettes with instant AI-powered pathophysiology rationales.

Clinical Significance & Diagnostic Standard
2026 Clinical Reference

What is the HOMA-B?

📋Clinical Summary & Definition Capsule

The HOMA-B is an evidence-based clinical decision rule engineered to quantify diagnostic probability, stratify clinical severity, and guide therapeutic decision-making in endocrinology & metabolism practice. The Homeostatic Model Assessment of Beta-cell function (HOMA-B) estimates the steady-state beta-cell function as a percentage of a normal healthy reference population. Clinical scoring tools like HOMA-B are essential in acute and outpatient management, enabling clinicians to objectively differentiate between low-risk candidates suitable for conservative therapy and high-risk patients requiring urgent interventions. Verified against current 2026 clinical standards, this tool is extensively tested on Gulf health authority licensing exams including DHA (Dubai), SMLE (Saudi Arabia), MOH, HAAD/DOH (Abu Dhabi), OMSB (Oman), and QCHP (Qatar).

💡Clinical Pearls & Diagnostic Utility

Helps distinguish whether hyperglycemia is primarily driven by insulin resistance (high HOMA-IR) or beta-cell failure (low HOMA-B).

Mathematical Formulation

Formula & Calculation Parameters

The mathematical equation and clinical variables required to calculate HOMA-B:

HOMA-B (%) = (360 × Fasting Insulin [µU/mL]) / (Fasting Glucose [mg/dL] - 63)
(Note: If glucose is in mmol/L, formula is (20 × Insulin) / (Glucose - 3.5))
Risk Stratification

Score Interpretation & Clinical Stratification

Score RangeClinical InterpretationRisk Tier
≤ 50Low Beta-Cell Functionred
50 – 100Borderline to Normalyellow
≥ 100Normal/High (Compensatory)green
Clinical Limitations & Contraindications

When to Exercise Caution

Not valid if fasting glucose is ≤ 63 mg/dL. Not validated for use in patients receiving exogenous insulin therapy. Less accurate in severe hyperglycemia (glucose toxicity).

Medical Review & Guidelines Compliance
MD

Clinical Review Board

Dr. Muhammad Nouman, MBBS

Capital Medical University | PMDC Reg No: 117744-P

Clinical Audit Status

✓ Verified for 2026 Guidelines

Last updated: 2026-08-07

Peer-Reviewed Medical Literature

  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.